Cargando…
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown in recent randomized placebo-controlled studies. Therefore, we investigated th...
Autores principales: | Kitao, Naoyuki, Miyoshi, Hideaki, Furumoto, Tomoo, Ono, Kota, Nomoto, Hiroshi, Miya, Aika, Yamamoto, Chiho, Inoue, Atsushi, Tsuchida, Kenichi, Manda, Naoki, Kurihara, Yoshio, Aoki, Shin, Nakamura, Akinobu, Atsumi, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634845/ https://www.ncbi.nlm.nih.gov/pubmed/29017497 http://dx.doi.org/10.1186/s12933-017-0607-6 |
Ejemplares similares
-
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)
por: Nomoto, Hiroshi, et al.
Publicado: (2016) -
A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
por: Nomoto, Hiroshi, et al.
Publicado: (2015) -
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018) -
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018) -
Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
por: Cho, Kyu Yong, et al.
Publicado: (2018)